Clinical trials: Resistant Depression, Treatment
Major Depressive Disorder
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
The investigators propose to determine if 8 weeks of dietary augmentation with oral 5g creatine monohydrate daily and 100 mg of 5-hydroxytryptophan (5-HTP) twice daily reduces hypoxia-related depressive symptoms measured by the…
- Trial name
- NCT02922725
- Testing
- 5-hydroxytryptophan and Creatine
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brent Michael Kious, MD, PhD
Insulin Resistance, Depression
Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes
The investigators are doing this study to learn more about how to prevent type 2 diabetes in teenage girls. The purpose of this study is to find out if taking part in a cognitive-behavioral therapy group, exercise training group…
- Conditions
- Insulin Resistance, Depression, Depressive Disorder, Mood Disorders
- Trial name
- CBTeX (NCT05543083)
- Testing
- Cognitive-Behavioral Therapy followed by Exercise Training, Exercise Training followed by Cognitive-Behavioral Therapy, Cognitive-Behavioral Therapy Only
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Treatment-Resistant Depression
Focal Electrically Administered Seizure Therapy for the Treatment of Depression
The purpose of this study is to determine the efficacy and any possible side effects of focal electrically administered seizure therapy (FEAST) as a treatment intervention for patients with recurrent and treatment resistant…
- Trial name
- FEAST (NCT02462551)
- Testing
- Focal Electrically Administered Seizure Therapy
- Where
- Lebanon
- Volunteers
- 30 people
- Sponsor
- Ziad Nahas
Major Depressive Disorder, Treatment Resistant Depression
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
This is a feasibility study and the goal of this project is to evaluate whether peak ACC GABA and glutamate, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical…
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
- Trial name
- NCT03573349
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Treatment Resistant Depression, Major Depressive Disorder
Predictors of Intravenous Ketamine Response in TRD
For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT05625555
- Testing
- Ketamine, Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abraham Nunes
Treatment Resistant Depression
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID KOR (NCT01913535)
- Testing
- CERC-501
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Treatment-resistant Bipolar Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment…
- Trial name
- NCT03522545
- Testing
- Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Major Depressive Disorder
D-cycloserine for Major Depressive Disorder
For many depression patients treatment changes are required, including switching to another antidepressant and addition of a second antidepressant or a non-antidepressant agent ("augmentation").
- Trial name
- NCT00408031
- Testing
- D-cycloserine
- Where
- 2 sites in Israel
- Volunteers
- 26 people
- Sponsor
- Herzog Hospital
Treatment Resistant Depression
Open Label - Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
- Trial name
- NCT06052137
- Testing
- Active TBS-DLPFC, TBS-DMPFC
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Stanford University
Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation
Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed Patients
Depression is the leading cause of disability worldwide and around 800,000 suicides occur each year. According to the World Health Organization, major depressive disorder (MDD) is expected to be the leading cause of the global…
- Conditions
- Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation, Accelerated Protocol, Sham-controlled
- Trial name
- NCT06783361
- Testing
- Transcranial Magnetic Stimulation with figure-eight coil
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Major Depression Disorder
Molecular Signatures of TMS Response in Treatment-Resistant Depression
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD).
- Trial name
- PROMET_TMS (NCT07039370)
- Testing
- TMS
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Depression
Cognitive Markers of Response to Treatment in Resistant Depression
Patients with depression are frequently treatment resistant. Clinical manifestations of depression are various, but cognitive dysfunctions are commonly present. Many factors are involved in treatment resistance.
- Trial name
- DEP-ICOR (NCT02774980)
- Testing
- Recurrent depression
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depression, Anxiety Disorders
Cognitive and Drug Therapy for Drug-Resistant Depression
To develop an effective combined cognitive therapy (CT) plus drug treatment for patients with drug-resistant depression (DRD) (i.e., depression that is refractory to medication).
- Conditions
- Depression, Anxiety Disorders, Personality Disorders, Drug-resistant Depression
- Trial name
- NCT00000376
- Testing
- Cognitive therapy, Desipramine
- Sponsor
- University of Pennsylvania
Depressive Disorder, Treatment-Resistant
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
This study evaluates the efficacy and safety of ethosuximide in the treatment of refractory depressive disorder in adults. Half of participants will receive ethosuximide and escitalopram in combination, while the other half will…
- Trial name
- NCT03887624
- Testing
- Ethosuximide, Escitalopram
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang University
Treatment-resistant Depression (TRD)
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions.
- Trial name
- PSI-GROUP (NCT07737990)
- Testing
- Group integration therapy
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- Joshua Rosenblat
Treatment Resistant Depression, Epilepsy
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
The overall goal of this study is to map the spatiotemporal dynamics of social affective processing and to examine selective modulation of these dynamics in humans undergoing invasive intracranial monitoring for…
- Trial name
- NCT05418894
- Testing
- Device: Directional Deep Brain Stimulation
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine